Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas

Trial Profile

A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2019

At a glance

  • Drugs Pembrolizumab (Primary) ; Irinotecan; Paclitaxel
  • Indications Neuroendocrine carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Feb 2019 The segments and indications from the inclusion criteria are not very clear, hence have not added it. Its better to wait for the final results for the correct info.
    • 19 Jan 2019 Preliminary results from Part A Stage 1 (n=14) presented at the 2019 Gastrointestinal Cancers Symposium
    • 05 Jun 2018 According to trial design presented at 54th Annual Meeting of the American Society of Clinical Oncology, current enrollment: 5 of planned 14 patients in stage I of Part A (6/2017-present).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top